August 6, 2025 08:00 AM Eastern Daylight Time
Retension Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases, today announced the successful closing of its $15 million Series B financing to advance the clinical development of RTN-001 for patients with uncontrolled and resistant hypertension.
Retension Pharmaceuticals also announced the issuance of US Patent Number 12,258,350 covering preferred crystalline polymorph forms of RTN-001 that will provide extended patent protection through at least 2044.
News
August 21, 2024 07:00 AM Eastern Daylight Time
Retension Pharmaceuticals is a clinical-stage therapeutic development company focused on developing innovative treatments for hypertension and cardiovascular disease. The company's lead drug candidate, RTN-001, a second generation PDE5 inhibitor, was designed to target the tissues of the higher vasculature by the company’s CSO and Co-Founder, Dr. Paul Sweetnam, overcoming the limitations of first generation PDE5 inhibitors in the hypertension space. According to the WHO, it is estimated that hypertension affects 1.28 billion adults worldwide, of whom only 21% have their hypertension fully under control. In prior clinical trials, RTN-001 has been studied in over 265 human subjects, including two Phase 2 studies in patients with uncontrolled hypertension. In these studies, RTN-001 was shown to be well tolerated and demonstrated clinically significant blood pressure lowering effects.